Entero Therapeutics Inc expected to post a loss of $1.55 a share - Earnings Preview

GridAI Technologies

06/09/2024 21:20

* Entero Therapeutics Inc  ENTO.OQ   ENTO.O  is expected
to show
no change in quarterly revenue when it reports  results on
September 9 (estimated) for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Entero Therapeutics Inc
is for
a loss of $1.55 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Entero
Therapeutics Inc is $36.00​, above​ its last closing price
of $0.40. ​​​

This summary was machine generated September 6 at 20:20 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)